- UBS has upgraded shares of Alnylam Pharmaceuticals (ALNY +1.8%) from hold to buy and boosted its price target to $215 (~12% upside).
- Analyst Esther Rajavelu says that over the next year to two years, "we expect continued uptake in revenues and meaningful value inflections tied to the pipeline including likely approval of Vutrisiran in [transthyretin-mediated ("ATTR") amyloidosis], Leqvio (partnered) in dyslipidemia, Onpattro Phase 3 data in ATTR-[cardiomyopathy], and Zilebesiran Phase 2 data in hypertension."
- She adds the company may surpass 5-year revenue CAGR of 40%.
- Rejavalu notes that Alnylam is "well positioned for commercial execution."
- Alnylam completed enrollment in a phase 3 trial of Vutrisiran in August.
UBS upgrades Alnylam to buy; sees 5-year revenue CAGR surpassing 40%
Recommended For You
More Trending News
About ALNY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALNY | - | - |
Alnylam Pharmaceuticals, Inc. |